中文｜English
ISSN 1001-5256 (Print)
ISSN 2097-3497 (Online)
CN 22-1108/R
Menu
Volume 36 Issue 8
Aug.  2020
Turn off MathJax
Article Contents
Abstract
References
Article Navigation >  Journal of Clinical Hepatology  > 2020  >  36(8): 1747-1752

Clinical features of rebleeding after secondary prevention for esophagogastric variceal bleeding in cirrhotic portal hypertension

DOI: 10.3969/j.issn.1001-5256.2020.08.014

  • First Liver Cirrhosis Diagnosis and Treatment Center, The Fifth Medical Center of Chinese PLA General Hospital

Research funding:

 

  • Published Date: 2020-08-20
    Abstract

  • ObjectiveTo investigate the clinical manifestations, emergency endoscopic diagnosis and treatment, and prognosis of rebleeding after different secondary prevention measures for esophagogastric variceal bleeding in cirrhotic portal hypertension. MethodsA retrospective analysis was performed for the clinical data of 254 patients with rebleeding after secondary prevention (endoscopic therapy, surgical treatment, or interventional prevention) for esophagogastric variceal bleeding who underwent emergency endoscopic diagnosis and treatment in The Fifth Medical Center of Chinese PLA General Hospital from January 2018 to April 2019, and 419 patients who received medication alone for the prevention of rebleeding during the same period of time were enrolled as controls. Clinical features were observed and compared between groups. An analysis of variance was used for comparison of normally distributed continuous data between groups, and the Kruskal-Wallis H test was used for comparison of continuous data with heterogeneity of variance between groups. The least significant difference Bonferroni test was used for further comparison between two groups. The chi-square test  was used for comparison of categorical data between groups. ResultsAmong the 254 patients with rebleeding after secondary prevention, 144 (56.69%) received endoscopic prevention, 40 (15.75%) received surgical prevention, 33 (12.99%) received interventional prevention, and 37(14.57%) received prevention with endoscopy combined with other prevention measures. As for the time from last prevention to bleeding, 57.50% in the surgical prevention group had a time of more than 5 years, and 69.70% in the interventional prevention group experienced bleeding within 1 year after transjugular intrahepatic portosystemic shunt; 40.28% in the endoscopic prevention group and 35.14% in the combined prevention group experienced rebleeding within 1 year after prevention ended. During rebleeding, the interventional prevention group and the combined prevention group had a significantly higher incidence rate of hepatic encephalopathy than the other groups (all P＜0.001), and the interventional prevention group had significantly better controlled ascites than the other groups (all P＜0.05). There were significant differences in various clinical indices between these groups during rebleeding (all P＜0.001), and the endoscopic prevention group had significantly higher levels of hemoglobin and albumin than the surgical prevention group (P＜0.001 and P=0.001) and the medication prevention group (P=0.001 and P＜0.001). The surgical prevention group had a significantly higher platelet count than the interventional prevention group (P=0.037), the combined prevention group (P＜0.001), and the medication prevention group (P=0.012). The medication prevention group had a significantly higher level of bilirubin than the endoscopic prevention group (P=0.037), the interventional prevention group (P=0.025), and the combined prevention group (P＜0.001); the surgical prevention group had a significantly higher level of creatinine than the other four groups (all P＜0.05); the combined prevention group had significantly better coagulation parameters prothrombin time and international normalized ratio than the medication prevention group (both P=0.002). The medication prevention group had a significantly higher proportion of patients with active bleeding than the endoscopic prevention group (P＜0.001), the interventional prevention group (P=0.004), and the combined prevention group (P=0.008). The surgical prevention group and the medication prevention group had a significantly higher proportion of patients with esophageal variceal bleeding than the other groups (all P＜0.05), and the interventional prevention group had a significantly higher proportion of patients with peptic ulcer and bleeding than the other four groups (all P＜0.05). The medication prevention group had significantly higher dissatisfaction rate and failure rate of endoscopic treatment than the endoscopic prevention group (P＜0.001), the interventional prevention group (P=0.007), and the combined prevention group (P＜0.001). The medication prevention group had significantly higher rebleeding rate and mortality rate within 42 days than the other four groups (all P＜0.05). Conclusion Compared with medication prevention alone, interventional prevention, endoscopic prevention, or combined secondary prevention can significantly alleviate the degree of esophagogastric variceal rebleeding, improve the hemostatic rate of emergency endoscopy, and significantly reduce rebleeding rate and mortality rate within 42 days. The clinical features of rebleeding after different secondary prevention measures should be considered to perform individualized treatment of patients with rebleeding after secondary prevention for esophagogastric variceal bleeding.

     

    • FullText(HTML)
    • References(14)
  • [1]GARCA-PAGN JC,REVERTER E,ABRALDES JG,et al.Acute variceal bleeding[J].Semin Respir Crit Care Med,2012,33(1):46-54．
    [2]Chinese Society of Hepatology,Chinese Medical Association;Chinese Society of Gastroenteroloty,Chinese Medical Association;Chinese Society of Endoscopy,Chinese Medical Association.Guidelines for the diagnosis and treatment of esophageal and gastric variceal bleeding in cirrhotic portal hypertension[J].J Clin Hepatol,2016,32(2):203-219.(in Chinese)中华医学会肝病学分会，中华医学会消化病学分会，中华医学会内镜学分会．肝硬化门静脉高压食管胃静脉曲张出血的防治指南[J]．临床肝胆病杂志，2016,32(2):203-219．
    [3]Portal Hypertension Group,Chinese Society of Surgery,Chinese Medical Association.Expert consensus on the diagnosis and treatment of esophagogastric variceal bleeding in cirrhotic portal hypertension[J].Chin J Pract Surg,2015,35 (10):1086-1090.(in Chinese)中华医学会外科学分会门静脉高压症学组．肝硬化门静脉高压症食管、胃底静脉曲张破裂出血诊治专家共识(2015)[J]．中国实用外科杂志，2015,35(10):1086-1090．
    [4]Interventional Group,Chinese Society of Radiology,Chinese Medical Association.Expert consensus on transjugular intrahepatic portosystemic shunt[J].J Clin Hepatol,2017,33 (7):1218-1228.(in Chinese)中华医学会放射学分会介入学组．经颈静脉肝内门体分流术专家共识[J]．临床肝胆病杂志，2017,33(7):1218-1228．
    [5]DENG H,QI XS,GUO XZ.UK guidelines on the management of variceal haemorrhage in cirrhotic patients (2015):An excerpt of recommendations[J].J Clin Hepatol,2015,31 (6):852-854.(in Chinese)邓晗，祁兴顺，郭晓钟．《2015年英国肝硬化静脉曲张出血防治指南》摘译[J]．临床肝胆病杂志，2015,31(6):852-854．
    [6]CHENG LF,LI CZ.A multi-center survey of esophagogastic variceal bleeding in China[J].J Clin Hepatol,2012,28 (6):462-464.(in Chinese)程留芳，李长政．全国多中心食管胃静脉曲张出血调查[J]．临床肝胆病杂志，2012,28(6):462-464．
    [7]Chinese Society of Hepatology,Chinese Medical Association.Chinese guidelines on the management of liver cirrhosis[J].JClin Hepatol,2019,35(11):2408-2425.(in Chinese)中华医学会肝病学分会．肝硬化诊治指南[J]．临床肝胆病杂志，2019,35(11):2408-2425．
    [8] Chinese Society of Spleen and Portal Hypertension Surgery,Chinese Society of Surgery,Chinese Medical Association.Expert consensus on diagnosis and treatment of esophagogastric variceal bleeding in cirrhotic portal hypertension (2019edition)[J].Chin J Dig Surg,2019,18 (12):1087-1093.(in Chinese)中华医学会外科学分会脾及门静脉高压外科学组．肝硬化门静脉高压症食管、胃底静脉曲张破裂出血诊治专家共识(2019版)[J]．中华消化外科杂志，2019,18(12):1087-1093．
    [9]LEE SW,LEE TY,CHANG CS.Independent factors associated with recurrent bleeding in cirrhotic patients with esophageal variceal hemorrhage[J].Dig Dis Sci,2009,54(5):1128-1134．
    [10]CHEN LG,YE ZS,REN JL,et al.The short-term effect and saftety analysis of endoscopic esophageal variceal ligation[J].Jilin Med J,2014,35(34):7586-7588.(in Chinese)陈立刚，叶震世，任建林，等．内镜食管静脉曲张套扎术的短期疗效和安全性分析[J]．吉林医学，2014,35(34):7586-7588．
    [11]CAO YJ,PAN YM,BAO SH,et al.Analysis of prognostic factors of portal hypertension treated with devascularization[J].Chin J Surg,2016,54(6):434-438.(in Chinese)曹亚娟，潘一明，包善华，等．断流术治疗门静脉高压症的预后影响因素分析[J]．中华外科杂志，2016,54(6):434-438．
    [12]ZENG DB,DI L,DING J,et al.Clinical efficacy of devascularization in treatment of esophageal and gastric varices in cirrhosis patients with portal hypertension[J/CD].Chin J Hepat Surg:Electronic Edition,2019,8(4):306-310.(in Chinese)曾道炳，邸亮，丁兢，等．断流术治疗肝硬化门静脉高压症食管胃静脉曲张疗效[J/CD]．中华肝脏外科手术学电子杂志，2019,8(4):306-310．
    [13]LING WM,LI HF,HUANG QL.Effect of splenectomy combined with pericardial vascular dissection on liver function and hemodynamics in patients with cirrhosis of the portal vein[J/CD].Chin Arch Gen Surg (Electronic Edition),2018,12(2):115-119.(in Chinese)凌伟明，李鸿飞，黄庆录．脾切除联合贲门周围血管离断术对肝硬化门静脉高压症患者肝功能及血流动力学的影响[J/CD]．中华普通外科学文献(电子版)，2018,12(2):115-119．
    [14]TAN J,ZHOU M,DENG QZ,et al.Transjugular intrahepatic portosystemic shunt (TIPS) for gastroesophageal variceal bleeding in cirrhotic patients with portal hypertension:A 2-year clinical outcomes surveillance study[J].Zhejiang Med J,2019,41(11):1138-1142.(in Chinese)谭俊，周密，邓勤智，等．经颈静脉肝内门体分流术治疗肝硬化门静脉高压症并发食管胃底静脉曲张破裂出血2年生存分析[J]．浙江医学，2019,41(11):1138-1142.
    • Relative Articles

  • Relative Articles

    [1]Wei YAN, Huifang HUANG. Effect of glucocorticoid in the treatment of severe drug-induced liver injury[J]. Journal of Clinical Hepatology, 2022, 38(10): 2302-2307. doi: 10.3969/j.issn.1001-5256.2022.10.019
    [3]Yu HE, Jidong JIA, Ping WANG. Research advances in the role of the glucocorticoid-induced tumor necrosis factor receptor-related protein and its ligand in liver diseases[J]. Journal of Clinical Hepatology, 2021, 37(7): 1718-1723. doi: 10.3969/j.issn.1001-5256.2021.07.051
    [4]Long LIU, Yao LIU, Fangyuan GAO, Xianbo WANG. Clinical features of chronic liver disease with autoimmune blood diseases and the clinical effect of glucocorticoid[J]. Journal of Clinical Hepatology, 2021, 37(8): 1878-1882. doi: 10.3969/j.issn.1001-5256.2021.08.025
    [5]Yang Jun, Hu ZhongJie, Zhu YueKe, Yu HongWei, Li Juan, Hou Wei, Ning QiQi. Clinical effect of glucocorticoids versus pentoxifylline in patients with severe alcoholic liver disease: A Meta-analysis[J]. Journal of Clinical Hepatology, 2019, 35(7): 1546-1550. doi: 10.3969/j.issn.1001-5256.2019.07.025
    [6]Zhao YouYou, Zhang Duan, Yin Xin, Wen XiaoYu, Gao PuJun. Glucocorticoid treatment of intrahepatic cholestasis caused by infectious cholangitis: A case report[J]. Journal of Clinical Hepatology, 2019, 35(2): 386-387. doi: 10.3969/j.issn.1001-5256.2019.02.031
    [7]Ma Juan, Liu YuLan. Corticosteroid therapy for autoimmune pancreatitis[J]. Journal of Clinical Hepatology, 2018, 34(8): 1599-1603. doi: 10.3969/j.issn.1001-5256.2018.08.002
    [9]Wang XiuFang, Feng GuoHe. Research advances in glucocorticoids for the treatment of liver failure[J]. Journal of Clinical Hepatology, 2018, 34(7): 1565-1568. doi: 10.3969/j.issn.1001-5256.2018.07.043
    [10]Meng QingHua. Timing of glucocorticoid therapy for liver failure[J]. Journal of Clinical Hepatology, 2017, 33(9): 1683-1686. doi: 10.3969/j.issn.1001-5256.2017.09.011
    [11]Liu LiBin, Wang Min, Tian YueLi, Cong Jing, Wang LiYing. Severe fatty liver induced by glucocorticoids: a report of one case[J]. Journal of Clinical Hepatology, 2016, 32(1): 161-162. doi: 10.3969/j.issn.1001-5256.2016.01.034
    [12]Qiu Bo, Zhu Ling, Wang TangMing, Yan ShiChun, Zhang JianMing, Xie ZhiAn, Liu XingYu. Efficacy of low-dose glucocorticoids in treatment of HBV-related acute-on-chronic liver failure[J]. Journal of Clinical Hepatology, 2016, 32(7): 1300-1304. doi: 10.3969/j.issn.1001-5256.2016.07.017
    [13]Chang BinXia, Teng GuangJu, Sun Ying, Zhao Jun, Zhang Wei, Zou ZhengSheng, Li BaoSen. Drug-induced liver injury caused by treatment of complications after glucocorticoid therapy for panniculitis: a report of one case[J]. Journal of Clinical Hepatology, 2015, 31(5): 775-776. doi: 10.3969/j.issn.1001-5256.2015.05.035
    [14]Ge HongYan, Wang YingShu. Clinical efficacy of glucocorticoid therapy in treatment of drug-induced cholestatic liver disease[J]. Journal of Clinical Hepatology, 2015, 31(10): 1618-1620. doi: 10.3969/j.issn.1001-5256.2015.10.014
    [15]Zhou XinMin, Dong XuYang. Therapeutic strategies of liver failure for clinical cases[J]. Journal of Clinical Hepatology, 2012, 28(2): 93-98.
    [16]Wang Meng, Nie QingHe. Meta-analysis of the efficacy and complications of glucocorticoids in patients with severe hepatitis-related liver failure [J]. Journal of Clinical Hepatology, 2012, 28(10): 764-770.
    [17]Zhou XianShan, Wan MoBin, Xue JianYa, Zhang Bin. Effects of glucocorticoids combined with antiviral therapy in treatment of patients with chronic severe hepatitis B.[J]. Journal of Clinical Hepatology, 2008, 24(2): 101-103.
    • Supplements(0)
    • Cited By

  • Cited by

    Periodical cited type(11)

    1. 朱惠刚，刘东升，贾楷桥. 腹腔镜下精准肝切除术与常规腹腔镜肝肿瘤切除术治疗原发性肝癌的效果及安全性. 中西医结合肝病杂志. 2022(07): 648-650 .
    2. 邓明，邓芳，陈志坚，周福生. 连翘苷对胃癌细胞AGS增殖、迁移和侵袭的抑制作用. 中成药. 2022(09): 3009-3012 .
    3. 赵金磊，季春勇，石伟，罗红杰，季予江，刘东亮. 长链非编码RNA MIAT在肝细胞癌组织中的表达及临床意义. 临床肿瘤学杂志. 2021(03): 217-221 .
    4. 侯亚萍，张小晶，李婷. 原发性肝癌患者LncRNA-MEG3表达与临床病理特征及预后的关系. 肝脏. 2021(07): 757-760 .
    5. 陈绪林，姜宇，赵艳，李彩华，高逸之. 原发性肝癌组织中miR-557的表达及其与预后的关系. 国际消化病杂志. 2021(04): 313-316 .
    6. 杜小梅，吕建宁，李雯. 长链非编码RNA EXOC7在非小细胞肺癌中的表达及临床意义分析. 临床肺科杂志. 2020(04): 592-595 .
    7. 林洁，黄炳臣，王娟，黄云美，黄小英. 肝癌患者组织及血清微小RNA-24和微小RNA-629的表达水平及其临床意义. 广西医学. 2020(14): 1775-1778 .
    8. 梅洪亮，黄致远，胡逸林，江艳，陈敏，卢绮萍，刘志苏. 长链非编码RNA KCNQ1重叠转录物1在肝细胞癌迁移及增殖和侵袭中的作用与机制研究. 中华消化外科杂志. 2020(10): 1083-1090 .
    9. 杨书才，张莉，刘利平，邓唯杰，周杰，刘慧，张鲍虎，金涛. 缺氧诱导因子2α对肝细胞癌化疗耐药性的影响. 中国临床药理学与治疗学. 2019(06): 630-636 .
    10. 钟蓝海，马丹丹，张智勇，张翌，蔡逊. 基于数据挖掘分析FAM134B在肝癌中的表达及其与预后的关系. 临床肝胆病杂志. 2019(11): 2508-2512 . 本站查看
    11. 唐丽，唐华，孙强. FOXM1、FOXO3a在肝癌中的表达及其临床意义. 临床医学研究与实践. 2019(36): 24-26 .

    Other cited types(3)

  • Created with Highcharts 5.0.7Amount of accessChart context menuAbstract Views, HTML Views, PDF Downloads StatisticsAbstract ViewsHTML ViewsPDF Downloads2024-052024-062024-072024-082024-092024-102024-112024-122025-012025-022025-032025-0405101520
    Created with Highcharts 5.0.7Chart context menuAccess Class DistributionFULLTEXT: 20.0 %FULLTEXT: 20.0 %META: 72.1 %META: 72.1 %PDF: 7.9 %PDF: 7.9 %FULLTEXTMETAPDF
    Created with Highcharts 5.0.7Chart context menuAccess Area Distribution其他: 7.6 %其他: 7.6 %其他: 0.9 %其他: 0.9 %Belgium: 0.5 %Belgium: 0.5 %Bengaluru: 0.1 %Bengaluru: 0.1 %China: 0.5 %China: 0.5 %India: 0.6 %India: 0.6 %Malvern: 0.1 %Malvern: 0.1 %Tuen Mun San Hui: 0.4 %Tuen Mun San Hui: 0.4 %United States: 0.5 %United States: 0.5 %[]: 1.2 %[]: 1.2 %上海: 3.2 %上海: 3.2 %上饶市铅山县: 0.1 %上饶市铅山县: 0.1 %东莞: 0.1 %东莞: 0.1 %乌鲁木齐: 0.1 %乌鲁木齐: 0.1 %佛山: 0.1 %佛山: 0.1 %保定: 0.1 %保定: 0.1 %兰州: 0.1 %兰州: 0.1 %加利福尼亚: 0.4 %加利福尼亚: 0.4 %加利福尼亚州: 0.4 %加利福尼亚州: 0.4 %北京: 16.1 %北京: 16.1 %十堰: 0.1 %十堰: 0.1 %南京: 0.7 %南京: 0.7 %南充: 0.1 %南充: 0.1 %南宁: 0.2 %南宁: 0.2 %南昌: 0.2 %南昌: 0.2 %南阳: 0.1 %南阳: 0.1 %印度泰米尔纳德: 0.1 %印度泰米尔纳德: 0.1 %厦门: 0.4 %厦门: 0.4 %合肥: 0.2 %合肥: 0.2 %吉安: 0.2 %吉安: 0.2 %吉林: 0.5 %吉林: 0.5 %呼和浩特: 0.2 %呼和浩特: 0.2 %哥伦布: 0.1 %哥伦布: 0.1 %太原: 0.4 %太原: 0.4 %安阳: 0.2 %安阳: 0.2 %宿迁: 0.1 %宿迁: 0.1 %常德: 0.1 %常德: 0.1 %广州: 2.5 %广州: 2.5 %张家口: 2.1 %张家口: 2.1 %成都: 0.1 %成都: 0.1 %新北: 0.4 %新北: 0.4 %无锡: 0.2 %无锡: 0.2 %昆明: 0.2 %昆明: 0.2 %晋城: 0.2 %晋城: 0.2 %格兰特县: 0.1 %格兰特县: 0.1 %武汉: 0.4 %武汉: 0.4 %沈阳: 0.2 %沈阳: 0.2 %波士顿: 0.4 %波士顿: 0.4 %泰州: 0.2 %泰州: 0.2 %济南: 1.0 %济南: 1.0 %济南市历城区: 0.4 %济南市历城区: 0.4 %济宁: 0.1 %济宁: 0.1 %海得拉巴: 0.4 %海得拉巴: 0.4 %深圳: 0.2 %深圳: 0.2 %深圳市龙华区: 0.1 %深圳市龙华区: 0.1 %湘潭: 0.2 %湘潭: 0.2 %湛江: 0.1 %湛江: 0.1 %眉山: 0.1 %眉山: 0.1 %石家庄: 0.2 %石家庄: 0.2 %红河哈尼族彝族自治州: 0.1 %红河哈尼族彝族自治州: 0.1 %芒廷维尤: 26.9 %芒廷维尤: 26.9 %芝加哥: 0.4 %芝加哥: 0.4 %莫斯科: 2.4 %莫斯科: 2.4 %衢州: 0.1 %衢州: 0.1 %西宁: 9.2 %西宁: 9.2 %西安: 1.2 %西安: 1.2 %诺沃克: 0.1 %诺沃克: 0.1 %贵阳: 0.1 %贵阳: 0.1 %赤峰: 0.2 %赤峰: 0.2 %运城: 2.0 %运城: 2.0 %遵义: 0.1 %遵义: 0.1 %邯郸: 0.1 %邯郸: 0.1 %郑州: 0.4 %郑州: 0.4 %重庆: 0.4 %重庆: 0.4 %长春: 6.3 %长春: 6.3 %长春市宽城区: 0.2 %长春市宽城区: 0.2 %长沙: 0.5 %长沙: 0.5 %长治: 0.2 %长治: 0.2 %阿什本: 0.5 %阿什本: 0.5 %青岛: 0.1 %青岛: 0.1 %香港: 0.2 %香港: 0.2 %驻马店: 0.1 %驻马店: 0.1 %黄冈: 0.2 %黄冈: 0.2 %其他其他BelgiumBengaluruChinaIndiaMalvernTuen Mun San HuiUnited States[]上海上饶市铅山县东莞乌鲁木齐佛山保定兰州加利福尼亚加利福尼亚州北京十堰南京南充南宁南昌南阳印度泰米尔纳德厦门合肥吉安吉林呼和浩特哥伦布太原安阳宿迁常德广州张家口成都新北无锡昆明晋城格兰特县武汉沈阳波士顿泰州济南济南市历城区济宁海得拉巴深圳深圳市龙华区湘潭湛江眉山石家庄红河哈尼族彝族自治州芒廷维尤芝加哥莫斯科衢州西宁西安诺沃克贵阳赤峰运城遵义邯郸郑州重庆长春长春市宽城区长沙长治阿什本青岛香港驻马店黄冈

Catalog

    通讯作者: 陈斌, bchen63@163.com
    • 1. 

      沈阳化工大学材料科学与工程学院 沈阳 110142

    1. 本站搜索
    2. 百度学术搜索
    3. 万方数据库搜索
    4. CNKI搜索
    Get Citation
    PDF
    XML

    Article Metrics

    Article views (1429) PDF downloads(195) Cited by(14)
    Proportional views
    Related
        

    The first journal specializing in hepatobiliary and pancreatic diseases in China

    Supervisor：Ministry of Education of the People's Republic of China

    Sponsor：Jilin University

    Academic Support: Chinese Society of Hepatology，Chinese Medical Association

    Address: 461 Xinjiang Road, Changchun

    Submit：0431-88782044

    Peer review：0431-88783542

    Email：lcgdb@vip.163.com

    About Journal

    Submission Guideline

    Journal Online

    Hepatobiliary College

    Guidelines

    YesterdayIP[2490]YesterdayPV[5108]TodayIP[1541]TodayPV[2861]Online[178]

    Website Design © 2020 Editorial Board of Journal of Clinical Hepatology 吉ICP备10000617号-1 Supported by: Beijing Renhe Information Technology Co. Ltd  

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return